Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ideaya Biosciences Q3 2026 Results: Net Loss of $126M

For the nine months ended September 30, 2026, IDEAYA Biosciences reported a net loss of $336.7 million, a significant increase from the $30.4 million loss in the prior year period, primarily due to a sharp decrease in collaboration revenue and increased R&D spending. The company strengthened its balance sheet through a follow-on public offering and warrant issuance, ending the period with approximately $1.15 billion in cash, cash equivalents, and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.2207.8
Net income-125.7119.2
EPS (diluted, $ a share)$-1.22$1.33

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-95.1%
Source

10-Q filed with the SEC, NASDAQ: IDYA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ideaya Biosciences, Inc.: key numbers

Share price
$30.36Close, Nov 16
Market cap
$2.94B
Shares outstanding
96.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ideaya Biosciences, Inc.

All →
8:05 AM ET 8-K
Financial Results

Ideaya Biosciences Financial Results

IDEAYA Biosciences reported Q3 2026 financial results, highlighting the completion of its first NDA submission for darovasertib in metastatic uveal melanoma. The company maintains a strong balance sheet with $1.15 billion in cash and equivalents, providing a projected cash runway into 2030.

Term
Q3 2026

“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma. We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.”

Yujiro S. Hata, Chief Executive Officer of IDEAYA
7:04 PM ET Form 4
Insider Selling

Ideaya Biosciences President and CEO Yujiro S. Hata Sells $985K of Stock

Yujiro S. Hata, President and CEO, sold 26,338 shares of Ideaya Biosciences, Inc. at $37.39 to $38.26 a share (average $37.41) in 2 transactions, worth $985K in total on Oct 6, 2026. Shares held after the trade: 690,695 (-0.1%).

Value
$985K
Shares
26,338
Average price
$37.41
Role
President and CEO
Holding change
-0.1%
Trade date
Oct 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.